Ingevity

NGVTNYSEUSD

THESIS ALERT

Email me when the NGVT thesis changes

Evidence-based analysis, not personalized investment advice. Every alert email carries an unsubscribe link.

Follow on X
$61.97
−$1.27 (−2.01%)Today 1M −10.28%
After hours$61.970.00%

Updated Nov 12, 4:00 PM ET · Regular session · May be delayed

Source valuation snapshot. Not a live recalculation.
Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
Diluted earnings per share from the latest filed annual.
$63.24
Prior regular-session close from the quote source.
$61.92–$63.44
Regular-session low and high so far today.
283.3K
Regular-session shares traded · Nov 12, 4:00 PM ET.
Feb 24 projected
Projected for 2027-02-24 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
$46.38–$79.29
52-week trading low and high returned by the quote source.

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

The core investment thesis

Own NGVT if Ingevity can become a higher‑margin, cash‑generative specialty materials company by exiting cyclical, low‑margin industrial businesses, focusing on Performance Materials and Pavement Technologies, and converting realized cost and footprint savings into durable operating profit and.

NGVT price history

Latest price$61.97Today−$1.27 (-2.01%)
NGVT -10.30%S&P 500 -2.67%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • Removing low‑margin, cyclical industrial specialties and capturing repositioning savings will sustain operating income and margins despite a smaller revenue base because the remaining businesses are higher‑value, mission‑critical products with pricing and margin resilience.StrengtheningMateriality: High

    OperatingIncomeLoss remained roughly stable at $452,600,000 (2022) → $423,200,000 (2023) → $425,900,000 (2024) → $418,700,000 (2025) even as revenue fell. If true, shareholders get durable operating profit and cash generation from a simpler portfolio; if false, profit will drift lower and the stock needs re‑rating downward or more capital actions.

    Watch: Failure to monetize remaining APT/pavement asset sales or need to retain low‑margin operations rather than sell.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    OperatingIncomeLoss remained roughly stable at $452,600,000 (2022) → $423,200,000 (2023) → $425,900,000 (2024) → $418,700,000 (2025) even as revenue fell.

    Open source ↗
  • Demand for mission‑critical products (automotive vapor control, filtration, pavement materials) plus operational savings will convert into stable operating cash flow, making earnings less sensitive to revenue cyclicality.HoldingMateriality: High

    NetCashProvidedByUsedInOperatingActivities: $313,400,000 (2022) → $205,100,000 (2023) → $128,600,000 (2024) → $331,200,000 (2025), showing a strong rebound in 2025. Sustained operating cash flow backs a higher multiple and funds buybacks/debt paydown; if cash flow is volatile, the company may need to access capital or sell assets.

    Watch: A macro downturn that reduces automotive or infrastructure activity materially (less traffic/infrastructure spend), lowering volumes in core end markets.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    NetCashProvidedByUsedInOperatingActivities: $313,400,000 (2022) → $205,100,000 (2023) → $128,600,000 (2024) → $331,200,000 (2025), showing a strong rebound in 2025.

    Open source ↗
  • Reported earnings will remain volatile until remaining strategic actions complete because prior impairments (e.g., road markings) show asset valuations are uncertain and sales processes can trigger additional write‑downs.StrengtheningMateriality: Medium

    NetIncomeLoss swung from $211,600,000 (2022) to negative results: $(5,400,000) (2023), $(430,300,000) (2024), $(167,100,000) (2025). If further impairments occur, book equity and investor returns will be damaged even if underlying operations are solid; avoiding new impairments is necessary for valuation recovery.

    Watch: Failure to complete sales of APT or remaining Performance Chemicals lines, forcing management to retain underperforming assets.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    NetIncomeLoss swung from $211,600,000 (2022) to negative results: $(5,400,000) (2023), $(430,300,000) (2024), $(167,100,000) (2025).

    Open source ↗
  • The balance sheet is fragile (very low reported equity), so management must either restore equity via earnings/cash flow or execute asset sales; otherwise the company risks forced capital actions or dilution.StrengtheningMateriality: Medium

    StockholdersEquity declined from $698,300,000 (2022) to $195,200,000 (2024) and to $29,700,000 (2025). Low equity increases the risk that an adverse event (another large impairment, covenant breach) forces fire sales or dilution that destroys expected returns.

    Watch: Inability to refinance or access capital markets on acceptable terms if needed (market disruption).

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    StockholdersEquity declined from $698,300,000 (2022) to $195,200,000 (2024) and to $29,700,000 (2025).

    Open source ↗
  • The current market valuation implies management will avoid further material impairments and will convert the repositioning savings into recurring operating income; to justify the stock, operating income and cash flow must remain near or above recent pre‑restructuring levels.HoldingMateriality: Medium

    OperatingIncomeLoss has been around $420–$452 million across 2022–2025 despite revenue declines. If management misses those execution milestones, the market will re‑rate the company downward even if top‑line recovery is slow.

    Watch: A new large impairment or restructuring charge that cuts operating income materially (e.g., another asset group impairment).

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    OperatingIncomeLoss has been around $420–$452 million across 2022–2025 despite revenue declines.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Removing low‑margin, cyclical industrial specialties and capturing repositioning savings will sustain operating income and margins despite a smaller revenue base because the remaining businesses are higher‑value, mission‑critical products with pricing and margin resilience. If true, shareholders get durable operating profit and cash generation from a simpler portfolio; if false, profit will drift lower and the stock needs re‑rating downward or more capital actions.

Demand for mission‑critical products (automotive vapor control, filtration, pavement materials) plus operational savings will convert into stable operating cash flow, making earnings less sensitive to revenue cyclicality. Sustained operating cash flow backs a higher multiple and funds buybacks/debt paydown; if cash flow is volatile, the company may need to access capital or sell assets.

Reported earnings will remain volatile until remaining strategic actions complete because prior impairments (e.g., road markings) show asset valuations are uncertain and sales processes can trigger additional write‑downs. If further impairments occur, book equity and investor returns will be damaged even if underlying operations are solid; avoiding new impairments is necessary for valuation recovery.

The balance sheet is fragile (very low reported equity), so management must either restore equity via earnings/cash flow or execute asset sales; otherwise the company risks forced capital actions or dilution. Low equity increases the risk that an adverse event (another large impairment, covenant breach) forces fire sales or dilution that destroys expected returns.

The current market valuation implies management will avoid further material impairments and will convert the repositioning savings into recurring operating income; to justify the stock, operating income and cash flow must remain near or above recent pre‑restructuring levels. If management misses those execution milestones, the market will re‑rate the company downward even if top‑line recovery is slow.

All standing thesis claims
Original report summary

Ingevity can become a higher‑margin, cash‑generative specialty materials company by exiting cyclical, low‑margin industrial businesses, focusing on Performance Materials and Pavement Technologies, and converting realized cost and footprint savings into durable operating profit and.

Evidence assessed Nov 12, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Ingevity

Where the evidence on Ingevity stands: Holding on the latest evidence (Nov 12, 2026). Of its 5 thesis points, 3 strengthening and 2 holding.

Bull case: what the evidence supports

  • Removing low‑margin, cyclical industrial specialties and capturing repositioning savings will sustain operating income and margins despite a smaller revenue base because the remaining businesses are higher‑value, mission‑critical products with pricing and margin resilience.

    sec.gov ↗

  • Demand for mission‑critical products (automotive vapor control, filtration, pavement materials) plus operational savings will convert into stable operating cash flow, making earnings less sensitive to revenue cyclicality.

    sec.gov ↗

  • Reported earnings will remain volatile until remaining strategic actions complete because prior impairments (e.g., road markings) show asset valuations are uncertain and sales processes can trigger additional write‑downs.

    sec.gov ↗

  • The balance sheet is fragile (very low reported equity), so management must either restore equity via earnings/cash flow or execute asset sales; otherwise the company risks forced capital actions or dilution.

    sec.gov ↗

  • The current market valuation implies management will avoid further material impairments and will convert the repositioning savings into recurring operating income; to justify the stock, operating income and cash flow must remain near or above recent pre‑restructuring levels.

    sec.gov ↗

Bear case: what would count against it

  • Failure to monetize remaining APT/pavement asset sales or need to retain low‑margin operations rather than sell.

    sec.gov ↗

  • A macro downturn that reduces automotive or infrastructure activity materially (less traffic/infrastructure spend), lowering volumes in core end markets.

    sec.gov ↗

  • Failure to complete sales of APT or remaining Performance Chemicals lines, forcing management to retain underperforming assets.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · Ingevity

12 mo agonow
Trailing daily price. No thesis break has crossed here, so there is no break base rate to project.

No break has crossed Ingevity’s thesis. Its break conditions are checked against every new filing as it lands.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Reported results of operations (earnings release).

    Ingevity filed an SEC 8-K on 2026-11-04: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  2. Mixed
    Reported results of operations (earnings release).

    Ingevity filed an SEC 8-K on 2026-07-29: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  3. Mixed
    Director or principal officer change.

    Ingevity filed an SEC 8-K on 2026-06-24: Director or principal officer change. It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Failure to monetize remaining APT/pavement asset sales or need to retain low‑margin operations rather than sell.
  • A macro downturn that reduces automotive or infrastructure activity materially (less traffic/infrastructure spend), lowering volumes in core end markets.
  • Failure to complete sales of APT or remaining Performance Chemicals lines, forcing management to retain underperforming assets.
  • Inability to refinance or access capital markets on acceptable terms if needed (market disruption).
  • A new large impairment or restructuring charge that cuts operating income materially (e.g., another asset group impairment).

NGVT news

Loading headlines…

Financial statements

NGVT income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

NGVT: quick answers

When does Ingevity (NGVT) report earnings next?
Ingevity's next results are projected for February 24, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 4, 2026. Earnings calendar
What is NGVT's short interest?
As of October 30, 2026, 1.3M NGVT shares were sold short, 3.71% of its shares outstanding, down 8.2% from the count before. At the stock's average daily volume that is 4.4 days to cover. FINRA publishes the count twice a month. NGVT short interest history
Have members of Congress traded NGVT?
1 trade in NGVT has been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed NGVT trade
Which well-known investors own NGVT?
1 of the 37 well-known funds tracked here reported NGVT shares in their latest 13F filing. By share of the fund's portfolio: Bridgewater Associates (Ray Dalio), 0.0%. Fund portfolios

NGVT in well-known investors’ portfolios

1 of 37 funds reported NGVT shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.

FundOf its portfolioValueChangeQuarter
Ray DalioBridgewater Associates0.01%$1.6M+19.8%Q2 2026

Every fund’s portfolio

ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.